首页> 外文期刊>Proceedings of Singapore Healthcare >Impact of tacrolimus versus cyclosporine on one-year renal transplant outcomes: A single-centre retrospective cohort study
【24h】

Impact of tacrolimus versus cyclosporine on one-year renal transplant outcomes: A single-centre retrospective cohort study

机译:Tacrolimus与环孢菌素对一年肾移植成果的影响:单中心回顾性队列研究

获取原文
           

摘要

Background: Calcineurin inhibitors are the cornerstone of maintenance immunosuppression after kidney transplant. While studies on predominantly Caucasian populations recommend tacrolimus over cyclosporine, the effects on Singapore’s local population remain unclear. Objectives: This study aimed to compare the impact of tacrolimus against cyclosporine on post-transplant outcomes in our local kidney transplant population. Methods: A single-centre retrospective chart review was conducted on ABO- and human leucocyte antigen (HLA)- compatible kidney transplantations between 1 January 2011 and 15 August 2018. Patients who received basiliximab induction, prednisolone, mycophenolate and either tacrolimus or cyclosporine were included and followed up for at least one year. Recipients of transplantations at other institutions or other immunosuppressive regimens were excluded. Patient and graft outcomes and adverse effects were collected. Results: Overall, 120 patients on tacrolimus and 49 on cyclosporine were included. Patients on tacrolimus were older. This group had more deceased donor transplants, a higher proportion with donor-specific antibodies (DSAs) present and more HLA mismatches. There were no differences in patient and graft survival, graft function and acute rejections at one year, despite adjusting for age, transplant type, presence of DSAs and total HLA mismatches. The tacrolimus group had more infectious admissions (odds ratio=0.27, 95% confidence interval 0.098–0.73, p=0.01) after adjusting for age, transplant type, HLA mismatches, presence of DSAs and acute rejections, with increased severity and more opportunistic infections. More patients on cyclosporine required a change to alternative immunosuppressants (p=0.003). Conclusion: Our study demonstrated comparable short-term post-transplant outcomes between cyclosporine and tacrolimus. Tacrolimus appears more tolerable but may be associated with infection risks.
机译:背景:钙素素抑制剂是肾移植后维持免疫抑制的基石。虽然主要是高加索人群的研究推荐Tacrolimus在环孢菌素上,但对新加坡当地人口的影响仍不清楚。目的:本研究旨在比较他克莫司对整个肾移植群体后移植后结果的影响。方法:在2011年1月1日至2018年8月15日至2018年1月1日至2018年8月15日之间进行单中心回顾性图表审查。包括Basiliximab诱导,泼尼松龙,霉酚酸酯和躯干或环孢菌素的患者并跟进至少一年。不包括在其他机构或其他免疫抑制方案的移植受体。收集患者和移植物结果和不良反应。结果:总体而言,包括120名患有Tacrolimus和49例环孢菌素的患者。他克莫司的患者年龄较大。该组有更多的死者移植,与供体特异性抗体(DSAS)的比例较高,并且具有更多HLA不匹配。尽管调整年龄,移植型,DSA的存在和总HLA不匹配,但患者患者和移植物生存率,移植物函数和急性排斥反应没有差异。在调整年龄,移植型,HLA不匹配,DSAS和急性排斥反应的调整后,Tacrolimus组具有更大的传染性入学(差距= 0.27,95%置信区间0.098-0.73,P = 0.01),具有增加的严重程度和更具机会主义感染。更多患者在环孢菌素上需要改变替代免疫抑制剂(p = 0.003)。结论:我们的研究表明,环孢素和躯干司之间的可比短期移植后果。 Tacrolimus似乎更容忍,但可能与感染风险相关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号